NBT Bank N.A. Buys New Shares in iShares Biotechnology ETF $IBB

NBT Bank N.A. purchased a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 22,752 shares of the financial services provider’s stock, valued at approximately $4,790,000.

Other large investors also recently made changes to their positions in the company. Pension & Wealth Management Advisors Inc. purchased a new stake in shares of iShares Biotechnology ETF in the second quarter valued at $28,000. Trust Co. of Vermont purchased a new position in iShares Biotechnology ETF during the second quarter worth about $44,000. GKV Capital Management Co. Inc. purchased a new position in iShares Biotechnology ETF during the first quarter worth about $49,000. Compass Financial Management LLC acquired a new stake in iShares Biotechnology ETF in the 2nd quarter worth about $56,000. Finally, Matrix Private Capital Group LLC acquired a new stake in iShares Biotechnology ETF in the 1st quarter worth about $68,000. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

IBB opened at $209.54 on Friday. The business has a 50-day moving average of $207.69 and a two-hundred day moving average of $189.17. iShares Biotechnology ETF has a 12 month low of $153.50 and a 12 month high of $217.12.

iShares Biotechnology ETF Cuts Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.0%. The ex-dividend date was Tuesday, September 15th. This is a decrease from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.